Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about VYNE THERAPEUTICS INC.
01/19VYNE Therapeutics Completes Phase 1b Data for FMX114 for Atopic Dermatitis
MT
01/19VYNE THERAPEUTICS : Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Trea..
PU
01/19VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Tre..
AQ
01/19VYNE Therapeutics Inc. Announces Phase 1B Data for Fmx114 from Phase 1B/2A Trial for th..
CI
01/14VYNE THERAPEUTICS : Unaudited Pro Forma Condensed Consolidated Financial Information - For..
PU
01/14VYNE Therapeutics Inc. Announces Board Changes
CI
01/14Health Care Stocks Drop Premarket Friday
MT
01/13Health Care Stocks Losing More Ground as Biotechs Sputter in Late Trade
MT
01/13Wall Street Set for Narrow Gains; US Wholesale Prices Rise Less Than Expected in Decemb..
MT
01/13Thinking about buying stock in Adagio Therapeutics, Vyne Therapeutics, PetVivo, BTCS In..
PR
01/13Journey Medical Acquires Vyne Therapeutics' Molecule Stabilizing Technology Franchise
MT
01/13VYNE THERAPEUTICS : Divests Topical Minocycline Assets - Form 8-K
PU
01/13VYNE Therapeutics Divests Topical Minocycline Assets
AQ
01/13Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and ..
CI
01/03VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access E..
AQ
2021VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from NASDAQ Biotechnology Index
CI
2021Top Premarket Gainers
MT
2021VYNE Therapeutics Shares Surge After HC Wainwright Starts Coverage at Buy
MT
2021HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target
MT
2021Thinking about buying stock in Del Taco Restaurants, Vyne Therapeutics, Lucid Group, AS..
PR
2021VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Confer..
AQ
2021VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
2021VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Up..
PU
2021VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Up..
AQ
2021Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $4.1M, vs. Street Est of $4.76..
MT
2021Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Loss $-0.36, vs. Street Est of $-0.3..
MT
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
2021Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass a..
PU
2021Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass a..
AQ
2021VYNE Therapeutics Inc. Announces Preclinical Data from Validated Animal Study Showing I..
CI
2021VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
AQ
2021Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm..
PU
2021Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm..
AQ
2021Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm..
CI
2021VYNE THERAPEUTICS : Announces Formation of Scientific Advisory Board
AQ
2021VYNE THERAPEUTICS : Enrolls First Patient in Trial of FMX114 to Treat Atopic Dermatitis; S..
MT
2021VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
PU
2021VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
AQ
2021VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment o..
CI
2021VYNE THERAPEUTICS : Partner Cutia Therapeutics Enrolls First Patient in Late-Stage Acne Dr..
MT
2021VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 ..
CI
2021VYNE THERAPEUTICS : to Present at the Cantor Fitzgerald Investment Conference
AQ
2021VYNE THERAPEUTICS : to Present at the H.C. Wainwright Annual Investment Conference
AQ
2021INSIDER TRENDS : Selling By Insiders Lingers at VYNE Therapeutics
MT
2021INSIDER TRENDS : Insider Sales Add to 90-Day Trend at VYNE Therapeutics
MT
2021INSIDER TRENDS : Insider 90-Day Selling Trend Prolonged at VYNE Therapeutics
MT
2021VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keep..
MT
2021VYNE THERAPEUTICS : Explanatory Note (Form 8-K)
PU
2021VYNE THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Announces New Strate..
PU
2021VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2..
CI
2021VYNE THERAPEUTICS : Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Loss $-0.35, vs. Stre..
MT
2021VYNE THERAPEUTICS : Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q2 Revenue $4.3M, vs. ..
MT
2021VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strat..
GL
2021VYNE THERAPEUTICS : Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory ..
AQ
2021VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory..
CI
2021Vyne Therapeutics Initiates Process to Explore A Sale or License of Its Topical Minocyc..
CI
2021VYNE THERAPEUTICS : Minocycline Products Cleared for Commercial Sale in Medical Tourism Pi..
MT
2021VYNE THERAPEUTICS : Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) i..
AQ
2021VYNE Therapeutics Inc. Announces Approval of Amzeeq (Minocycline) and Zilxi (Minocyclin..
CI
2021VYNE THERAPEUTICS : to Report Second Quarter 2021 Financial Results on August 12, 2021
AQ
2021VYNE THERAPEUTICS : Certificate of Amendment to the Amended and Restated Certificate of In..
PU
2021VYNE THERAPEUTICS : Says Austin Institute for Clinical Research Launches Study on Acne Com..
MT
2021VYNE THERAPEUTICS : Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ..
AQ
2021VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEE..
CI
2021Vyne Therapeutics Receives A Paragraph IV Certification Notice from Perrigo Israel Phar..
CI
2021VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digi..
GL
2021VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell 2500 Growth Index
CI
2021VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell 2000 Dynamic Index
CI
2021VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell Microcap Value Index
CI
2021VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell 2500 Index
CI
2021VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell 3000 Growth Index
CI
2021VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell 2500 Value Index
CI
2021VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell 2000 Growth Index
CI
2021VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell 2000 Value Index
CI
2021VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell 2000 Index
CI
1  2  3  4  5  6Next
Upcoming event on VYNE THERAPEUTICS INC.
03/03/22